Short Interest in Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Expands By 471.0%

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the target of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 39,400 shares, an increase of 471.0% from the January 31st total of 6,900 shares. Based on an average trading volume of 87,300 shares, the short-interest ratio is presently 0.5 days.

Inhibitor Therapeutics Price Performance

Inhibitor Therapeutics stock remained flat at $0.07 during midday trading on Thursday. The firm’s 50 day simple moving average is $0.06 and its 200-day simple moving average is $0.07. Inhibitor Therapeutics has a 12-month low of $0.04 and a 12-month high of $0.14. The company has a market cap of $11.36 million, a PE ratio of -6.59 and a beta of -0.56.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.